Shao-Lee Lin

Dr. Lin is an accomplished physician-scientist with over 20 years of academic and clinical research experience. Prior to her role as ACELYRIN’s chief executive officer, Dr. Lin previously served as executive vice president, head of R&D, and chief scientific officer at Horizon Therapeutics, where she built and led the R&D organization that advanced new treatments for patients with rare diseases. Prior to Horizon, Dr. Lin was a corporate officer leading therapeutic areas, development excellence, and international development at AbbVie. Dr. Lin earlier served as VP, Inflammation and Respiratory Development at Gilead and was responsible for multiple therapeutic areas at Amgen. Dr. Lin received her undergraduate degree in chemical engineering and biochemistry from Rice University. She received her M.D. and Ph.D. degrees at the Johns Hopkins University School of Medicine and held postdoc fellowships in Rheumatology, Allergy, and Immunology at UCSD and The Scripps Clinic and Research Institute. Throughout her career, Dr. Lin has held clinical and teaching appointments, first as Clinical Scholar at The Rockefeller University and adjunct faculty in Medicine at Cornell, and subsequently at UCLA, Stanford, and Northwestern.